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ABSTRACT
A Replication and Extension of a Prediction Tool Identifying Need for Treatment Among Opioid
Exposed Infants

by
Loni Parrish

The incidences of maternal opioid use and neonatal opioid withdrawal syndrome (NOWS) have
increased by nearly 400% over the past decade. Isemann and colleagues (2017) developed
prediction tools (TiTE/TiTE2) to differentiate, within the first two days of life, between infants
who will require pharmacotherapy for NOWS from those infants who will not require
pharmacotherapy for NOWS. The goal of the current experiment was to replicate and extend
their prediction model. The present experiments successfully replicated Isemann et al. (2017)
results and also established alternative cutoff values for requiring treatment that provide better
balance between all four metrics. Moreover, new prediction models (TEN/TEN 2) were proposed
based on a factor analysis of modified Finnegan scores across the first 48 hours of life. Area
Under the Curve-Receiver Operating Characteristic curve analyses indicated that the TEN2 was
the best prediction model compared to the TiTE2 and the TEN.
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Chapter 1. Introduction
Within the last few years, the number of women using opioids has increased dramatically
(Stover & Davis, 2015). Additionally, there has been a rise in the number of women using
opioids during pregnancy (Bateman et al., 2014; Handal, Engeland, Ronning, Skurtveit, & Furu,
2011; Lind et al., 2017). For example, the number of reported cases of opioid use during
pregnancy increased from 1.5 cases to 6.5 cases per 1000 delivery hospitalizations from 1999 to
2014 (Haight, Ko, Tong, Bohm, & Callaghan, 2018). The high rates of prescription and illicit
opioid use during pregnancy is a significant public health concern, not only for pregnant women,
but also for their fetuses. Opioids cross the placental and blood-brain barriers; thereby, posing
increased risk for fetuses who are exposed to such drugs in utero (Hudak & Tan, 2012). Some of
the common risks associated with prenatal opioid exposure include smaller head circumference
(Greig, Ash, & Douiri, 2012), premature birth (Azuine et al., 2019), and higher rates of
developing neonatal opioid withdrawal syndrome, or NOWS (Patrick, Davis, Lehman, &
Cooper, 2015). NOWS refers to the withdrawal symptoms that opioid-exposed neonates may
experience shortly after birth (Conradt et al., 2019). Similar to the rise in number of women
using opioids during pregnancy, the number of infants diagnosed with NOWS has increased.
Between 2000 and 2013, NOWS diagnoses increased from 1.2 cases to 5.8 cases per 1,000
hospital births (Conradt et al., 2019). The incidence rates of NOWS varies across the United
States with rates almost three times above the national average in Southern Appalachia (i.e.,
Kentucky, Tennessee, Mississippi, and Alabama) with approximately 16.2 cases of NOWS per
1,000 births (Patrick et al., 2015).
Not all infants with prenatal opioid exposure are diagnosed with NOWS. Research indicates
that between 50 – 80% of infants with prenatal opioid exposure are diagnosed with NOWS
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(Conradt et al., 2019). Consequently, it is important to predict which infants with prenatal opioid
exposure will be diagnosed with NOWS and require pharmacotherapy from those infants with
prenatal opioid exposure that will not be diagnosed with NOWS and thus not require
pharmacotherapy. This paper replicates a prediction tool for requiring and for not requiring
pharmacological treatment in a sample of infants at-risk for NOWS. Additionally, the current
paper extends and improves upon the prediction tool by teasing apart the impact of polydrug
exposure on the requirement of pharmacotherapy. Furthermore, a factor analysis was conducted
to see which items loaded together in this dataset and to improve the sensitivity of the prediction
tool.
Developmental Outcomes Associated with NOWS
The prenatal period is a critical time for brain development. When the fetus is exposed to a
teratogen, like an opioid, it can adversely affect brain development (Caritis & Panigrahy, 2019).
For instance, opioids can alter maturation in the connective tracts of the inferior and superior
fasciculi (Walhovd, Watts, CandPsychol, & Woodward, 2012), impair brain growth, and
promote neuronal death by apoptosis and necrosis (Yuan et al., 2014). These alterations in
neurodevelopment may contribute to cognitive and behavioral difficulties later in life.
Neonates with prenatal opioid exposure are at-risk for several adverse birth outcomes.
For example, neonates with prenatal opioid exposure are more likely to be born premature
(Azuine et al., 2019), have a longer stay in the hospital (Devlin, Lau, & Radmacher, 2017), have
lower birth weights (Ludlow, Evans, & Hulse, 2004), have higher NOWS rates (Patrick et al.,
2015), have more respiratory issues, feeding difficulties, and seizures (Patrick, Schumacher, &
Benny-Worth, 2012), have smaller head circumferences (Greig et al., 2012; Towers et al., 2019),
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and have a higher likelihood of fetal death (Kahila, Saisto, Kivitie-Kallo, Haukkammaa, &
Halmesmäki, 2007) than neonates without prenatal opioid exposure.
Research on the short- and long-term developmental outcomes associated with prenatal
opioid exposure has seen a recent increase but still remains limited and conflicting. There is data
that support that exposure to opioids in utero is associated with adverse developmental outcomes
(Yeoh, Eastwood, Wright, 2019), and there is data that support that prenatal opioid exposure is
not related to adverse outcomes (Kaltenbach et al., 2018). Research examining developmental
outcomes following a NOWS diagnosis is often muddled by the difficulty of properly defining
the population, finding an appropriate control group, and lack of strictly controlled data (i.e.,
consideration and inclusion of information on the home environment, SES, polysubstance use,
maternal characteristics, genetics, sex of newborn, prenatal care, and ethnicity) (Jones et al.,
2016).
Following prenatal opioid exposure, some research suggests that infants may experience
poor neurobehavior outcomes and motor delays (Bernstein, Jeremy, Hans, & Marcus, 1984;
Hans & Jeremy, 2001; McGlone & Mactier, 2015; Merhar et al., 2018). Specifically, opioidexposed infants have shown deficits in regulation, quality of movement, and excitement
(Bernstein et al., 1984; Velez et al., 2018) and delays in developmental milestones such as sitting
independently or crawling (Logan, Brown, & Hayes, 2013). In contrast, other research indicates
that there are no statistically significant differences between opioid-exposed infants’ motor
scores on the PDI compared to the standardized scores (Beckwith & Burke, 2014; Messinger et
al., 2004). An interesting pattern emerged in Hunt and colleagues’ (2008) investigation. They
found that there was no significant difference between opioid exposed infants and non-opioid
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exposed infants at 18 months but reported difference in motor performance around 3 years of age
(Hunt, Tziomi, Collins, & Jeffry, 2008).
In addition to motor development, research efforts have also investigated prenatal opioid
exposures association with cognitive performance. There is data suggesting that prenatal opioid
exposure is related to deficits in cognitive performance (Hans & Jeremy, 2001; Hunt et al., 2008;
Nygaard, Moe, Slinning, & Walhovd,2015). For example, researchers found that opioid-exposed
children, ranging from 18-28 months-old, had significantly lower scores on the cognitive and
language subscales of BSID-III compared to the normative population. This difference remained
even after consideration of the different types of opioid exposure (i.e., methadone,
buprenorphine, morphine), polysubstance use, length of hospital stay, gestational age, and birth
weight (Merhar et al., 2018). These cognitive differences may persist into older ages. For
example, Nygaard, Slinning, Moe, and Walhovd (2016) assessed children longitudinally at 4.5
and 8.5 years of age and found that children in the exposed group had scores that were more
predictive of attention difficulties in comparison to the control group at both ages. Moreover,
children with opioid exposure had lower test scores in reading, writing, numeracy, spelling, and
grammar than children without prenatal opioid exposure. Critically, children in 7th grade who
were diagnosed with NOWS as infants scored significantly lower than the controls in the 5th
grade (Oei et al., 2017). Collectively, these results suggest that a NOWS diagnosis and its
relation to lower cognitive performance in the first few years of life may continue later in life
and impact school performance.
In contrast, there are other researchers who have no found empirical support for differences
in cognitive performance following prenatal opioid exposure. For instance, Kaltenbach and
colleagues (2018) longitudinal study assessed child growth parameters, cognition, language
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abilities, sensory processing, and temperament between 0 and 36 months. There was insufficient
evidence to indicate that prenatal opioid exposure is associated with deficits in physical or
mental development. Moreover, Salo and colleagues (2010) found that, after controlling for birth
weight and height, gestational age, maternal age, SES, and number of foster placements,
differences on the cognitive scale of the Bayley-III between children exposed to opioids and
children not exposed to opioids were no longer significant. Finally, Bakhireva and colleagues
(2019) reported no neurodevelopmental delays (e.g., Bayley-III, IBQ-R) between infants with
prenatal opioid-exposure and infants without prenatal opioid exposure at 5-8 months of age.
The conflicting research on the developmental outcomes associated with prenatal opioid
exposure in the domains of motor and cognitive development could be due to difficulty
classifying infants as to whether they have NOWS. Current literature indicates that 50-80% of
infants with prenatal opioid exposure will be diagnosed with NOWS and require
pharmacotherapy to manage their withdrawal symptoms (Conradt et al., 2019). The use of
pharmacotherapy is subsequently related to longer hospital stays and increased cost of hospital
stays. If researchers can predict which opioid-exposed infants will require pharmacotherapy from
the opioid-exposed infants that will not require pharmacotherapy, then health care providers can
intervene earlier and potentially decrease the severity of the infants’ withdrawal symptoms and
length of stay in the hospital.
The American Academy of Pediatrics recommends that newborns with suspected prenatal
opioid exposure be observed in the hospital for 5-7 days for the development of withdrawal
symptoms. The Finnegan Neonatal Abstinence Scoring Tool (Finnegan, Connaughton, Kron, &
Emich, 1975; Jansson, Velez, & Harrow, 2009) is the most widely used measure for tracking and
quantifying the severity of the infant’s withdrawal symptoms over time. The Finnegan was first

11

published in 1975. The Finnegan has been modified since the original publication in an effort to
remove components that were no longer relevant (Finnegan et al., 1992). For example, individual
scores for excoriation on multiple body parts (i.e. nose, knees and toes) was revised to just a
single item called excoriation. The Modified Finnegan Neonatal Scoring System (MFNSS) also
organized items into three categories to help providers identify the most appropriate treatment
plan (Maguire, Cline, Parnell, & Tai, 2013). Most hospitals use the Modified Finnegan Neonatal
Scoring System (MFNSS), but it is commonly still referred to as “the Finnegan”. The MFNSS
consist of three sections with 21 items and 32 scoring options. The three sections are central
nervous system disturbances (CNS), metabolic vasomotor respiratory disturbances, and
gastrointestinal disturbances. Some of the CNS items consist of high-pitched cry, tremors, moro
reflex, and excoriation. Example items from the metabolic disturbances include sweating,
hyperthermia, nasal stuffiness, and respiratory rate. Lastly, a few items under gastrointestinal
disturbances are excessive sucking, poor feeding, loose stools, and vomiting. Most hospital
protocols dictate that if a newborn has three consecutive scores of greater than or equal to 8 or
two consecutive scores of greater than or equal to 12, then the provider should start
pharmacological treatment (Pomar et al., 2017). If the infant scores less than 8, then that
indicates that the infant’s withdraw is not severe enough for pharmacotherapy or the infant is
ready to be weaned off of the treatment drug (Pomar et al., 2017). One difficulty researchers
encounter when studying the relationship between MFNSS and treatment outcomes is that
clinicians also use their clinical decision-making skill set to guide treatment decisions. This
critical information is often not recorded in electronic medical records and thus a source of
unmeasured variability for retrospective chart reviews.
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Although the MFNSS is the most commonly used tool to assess the severity of neonatal
opioid withdrawal symptoms, it is not without limitations. First, the MFNSS was originally
designed as a standardized scoring tool for researchers not for guiding clinical treatment
decisions. Second, there has been very little empirical examination into the effectiveness of using
the common cutoff score of 8 to guide pharmacological treatment decisions. Zimmerman-Baer,
Notzli, Rentsch, and Bucher (2010) suggest that scores of 8 can differentiate between exposed
and non-exposed infants, but it does not provide any validation for the need for pharmacological
treatment following scores of 8 or greater (Gomez-Pomar & Finnegan, 2018). Finally, the
MFNSS contains several items that do not have a strong pathological significance to opioid
withdrawal in neonates (i.e., sneezing, yawning, and nasal stuffiness).
There are quite a few limitations associated with the MFNSS and its ability to quantify
the severity of an infant’s withdrawal symptoms. A recent alternative to the MFNSS has been
introduced in a few hospitals in the United States. Grossman, Minear, Whalen and Wachman
(2017) developed the Eat, Sleep, Console (ESC) approach because they believe that the start of
medication should not depend on the newborns Finnegan score, but rather on how well the
newborn is eating, sleeping and the newborns overall comfort level. This function-based
assessment tool continues to assess the newborns withdrawal symptoms, but the use of any type
of treatment depends on the overall comfort of the newborn (Grossman et al., 2017). ESC
assessments are initiated within 4-6 hours after birth and performed every 3-4 hours during
routine infant care. The ESC incorporates input from all of the newborn’s caregivers (e.g.
mother/parent, nurse, cuddler). Moreover, ESC assessments consist of a few questions that are
answered with a Yes or No. There are certain guidelines that help physicians choose the right
answer: Does the infant have poor feeding due to NAS?, Did the infant sleep for less than 1 hour
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after feeding due to NAS?, Is the infant unable to be consoled within 10 mins due to NAS. The
physician also rates the newborns ability to be consoled on a scale of 1 to 3. If the newborn
receives one “Yes” on any of the items, then a team huddle (i.e. parent, nurse, physician) is
required to look for next steps in non-pharmacologic care (e.g. skin to skin contact, swaddling,
quiet room, breastfeeding). If non-pharmacologic care does not work and the newborn continues
to score “Yes” on the ESC, then pharmacologic treatment will be considered (Grossman et al.,
2017).
Despite other models being created, the MFNSS is still the “gold standard” when it
comes to quantifying the severity of the newborn’s withdrawal symptoms and determining when
pharmacotherapy is prescribed by the provider. Currently, the MFNSS is not used to predict
which infants will require pharmacological treatment and which infants will not. However, there
are several prediction models available and they are discussed below.
Predicting Pharmacologic Treatment
Researchers have been working on developing a way to predict whether an infant will
require pharmacological treatment for their withdrawal or not. These predictions are important
because they could significantly reduce the length of the hospital stay for the infants, reduce
hospital stay cost, and enhance the caregiver-infant bond.
Oji-Mmuo and colleagues (2019) looked at the MFNSS to see whether it guided early
discharge for infants at-risk for NOWS before providing pharmacologic treatment. Researchers
examined hourly percentile curves of mean MFNSS scores in newborns being monitored for
NOWS over the first seven days of life. They found that higher percentile curves of the mean
MFNSS score were more likely to require pharmacologic treatment. Results showed that
newborns with mean MFNSS scores less than the 25th percentile at three days did not require
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pharmacologic treatment, suggesting that these newborns could be safely discharged without
further observation or intervention. Only a small percentage of newborns with MFNSS scores
less than the 50th percentile required treatment at three days, leading researchers to suggests these
newborns could also be safely discharged if families commit to close outpatient follow-up (OjiMmuo, Schaefer, Liao, Kaiser, & Sekhar, 2019). One consideration that limits the
generalizability and practicality of this prediction tool is that it does not factor polysubstance
exposure into the calculation of percentiles.
A second prediction model examined heart rate variability (HRV) parameters and their
relation to Finnegan scores and the need for pharmacotherapy for infants at-risk for NOWS
(Naguib, Alton, Avula, Hagglund, & Anne, 2014). HRV is a non-invasive way to look at
automatic cardiovascular function. Thus, Naguib and colleagues (2014) assessed HRV and
Finnegan scores in opioid-exposed newborns. Researchers compared HRV parameters of opioidexposed newborn to jaundice controls because newborns diagnosed with jaundice and opioidexposed newborns are placed in a similar hospital environment for observation. They found
lower HRV in the first 2 days of life in opioid-exposed newborns. Additionally, they found that,
in a span of three days, HRV parameters were cumulatively lower in the opioid-exposed group.
Furthermore, one HRV parameter was able to differentiate opioid-exposed newborns with
Finnegan scores greater than or equal to 8, from opioid-exposed newborns with Finnegan scores
less than 8. This is a critical finding because Finnegan scores of 8 are often used clinically to
start pharmacological treatment for withdrawal. Limitations of this study include the potential for
error in calculating HRV parameters and the manual labor and time intensiveness that are
required for calculating the HRV parameters. It is possible for neonates to wear a special monitor
that could automate this process, but it is in need of pilot testing.
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Finally, Isemann and colleagues (2017) developed a pair of tools (i.e., TiTE and TiTE²)
to predict the need for pharmacotherapy within the first 36 hours of life. The TiTE measures the
average score of three symptoms from the Finnegan (e.g., increased muscle tone, tremors when
disturbed, and excoriations) around 36 hours of life. The TiTE² incorporates exposure type into
the prediction model to enhance the predictive value. The TiTE tool predicted infants who would
require pharmacological treatment with positive predictive values of 90% and 100%. When
predicting infants who would receive pharmacotherapy, the TiTE² was able to accurately predict
infants who would receive pharmacological treatment with positive predictive values of 94% and
86% (Isemann, Stoeckle, Taleghani, & Mueller, 2017). Both prediction tools have high positive
predictive values but low sensitivity. The distribution of infants receiving treatment and those not
receiving treatment were analyzed to maintain thresholds that produced the highest positive
predictive value while maintaining greater than 25% sensitivity (Isemann et al., 2017).
Sensitivity and specificity metrics are related to the accuracy of a screening test relative
to a reference standard. In contrast, positive and negative predictive values assess the people.
Trevethan (2017) proposed that it is the positive predictive value that is most important for the
clinician. Sensitivity is the ability of a test to correctly classify people with the disease that will
have a positive result. If a test is highly sensitive and the test result is negative, you can be nearly
certain that they do not have the disease. A sensitive test helps “rule out” a disease (Parikh,
Mathai, Parikh, Sekhar, & Thomas, 2008). Specificity is the ability of a test to correctly classify
people without the disease that will have a negative test result. If a test is highly specific and the
test result is positive, you can be nearly certain that they have the disease. A specific test helps
“rule in” a disease (Parikh et al., 2008). Sensitivity and specificity are important for deciding
what diagnostic screener to use but mean very little to a patient who test positive or negative. On
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the other hand, positive predictive values present the probability of correctly identifying, from
among people who might or might not have a condition, all people who do actually have that
condition. Negative predictive values present the screening test’s probability of correctly
identifying, from among people who might or might not have a condition, all people who indeed
do not have that condition (Trevethan, 2017).
A high positive predictive value (minimizing false positives) is desirable because the
subsequent risks of starting pharmacological treatment are high (increased length of stay,
increased hospital cost, environmental stresses (NICU). However, it is also important to consider
the sensitivity of the test. With only 25% sensitivity that means 75% of cases may be false
positives. This is problematic because the test is designed to identify patients that can be sent
home early because their withdrawal symptoms are minimal. These patients may exhibit
withdrawal symptoms once home and the caregiver may not be prepared or know how to handle
those symptoms. Therefore, we aimed to modify the prediction tool to create a better balance
between the four metrics (i.e., sensitivity, specificity, positive predictive values, and negative
predictive values). Moreover, this study excludes cannabinoids from potential influence and has
oversimplified categories of polysubstance exposure. However, the current manuscript aims to
rectify these limitations by considering the influence of marijuana on the need for
pharmacological treatment and the inclusion of an additional polysubstance category.
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Chapter 2. Experiment 1A
Experiment 1A examined whether Isemann and colleagues’ (2017) TiTE and TiTE²
prediction tool’s sensitivity, specificity, positive predictive values, and negative predictive values
would replicate in an independent, retrospective, rural sample from the Appalachian Region. The
TiTE/TiTE² prediction model was selected over the other previously discussed prediction models
because it specifically investigates withdrawal symptoms that fall under the central nervous
system (CNS). Function of the CNS is of specific interest in the case of opioid-exposure because
opioid receptors are more concentrated in the CNS and gastrointestinal tract than other parts of
the body. As a result, withdrawal symptoms generally reflect CNS irritability, over reactivity,
and gastrointestinal tract dysfunction (Hudak & Tan, 2012). Additionally, this model lends itself
to easy adoption by hospitals as it would reduce the time to administer and score the Finnegan as
it only involves three items.
The TiTE and TiTE² were created and validated in single-center sample from an urban
area (University of Cincinnati Medical Center). The creation and validation were completed on
different samples of infants, but the validation sample only consisted of 121 infants. Applying
the prediction models to an independent sample nearly four times the size of the original sample,
from a different region of the United States, increases the generalizability of the prediction tools.
Experiment 1A served as a replication of Isemann and colleagues (2017) prediction model and
created the foundation for Experiment 1B in which the TiTE² exposure categories were adjusted
in attempt to better understand the effects of polysubstance exposure.
Methods
This retrospective chart review was approved by the East Tennessee State University
Medical IRB (0616.6sw-MSHA). An electronic medical record search for all deliveries between
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July 1, 2011 through June 20, 2016 was conducted. A total of 18,728 cases were returned. All
newborns with an ICD 9/10 code for NOWS or with prenatal opioid exposure (as determined by
a positive UDS or maternal report at delivery) were identified (n = 2638).
This is a unique research sample because the data was collected in the Appalachian
Region were the opioid epidemic is highly prevalent and, some areas, have approximately 50
cases of NOWS per 1000 hospital births (Miller, McDonald, & Warren, 2016). The mother’s and
infant’s medical records were used for data collection. Infant characteristics included in this
study are birth weight, gestational age, in utero opioid exposure, toxicology results,
pharmacological treatment, and individual symptoms scores that compose each of the Finnegan
scores collected during 0, 1, and 2 days of life. Maternal characteristics included drug use
history, drug toxicology results and socio-demographic information. For a complete summary of
infant and maternal characteristics of the sample see Table 1.
Table 1.
Summary of Infant and Maternal Characteristics
Variable
Maternal Age (years)
Number of Prenatal Care Visits
Used tobacco during pregnancy
Mother White
Mother Unmarried
Mother Graduated High School or Higher
WIC
Male Infants
Gestational Age (weeks)
Infant Length of Stay (days)
Infant Birthweight (grams)
Infant Head Circumference (cm)
APGAR 1 minute
APGAR 5 minutes
Breastfeeding

n
384
226
385
378
376
360
365
385
363
385
385
380
375
375
309
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Mean (SD)/Frequency (%)
26.89 (4.89)
8.68 (4.16)
326 (84.7%)
368 (95.6%)
275 (71.4%)
251 (69.7%)
285 (74.0%)
203 (52.7%)
38.18 (1.29)
11.50 (10.97)
2997.56 (435.88)
13.24 (0.63)
8.10 (0.86)
8.96 (0.50)
194 (50.4%)

TiTE scores were calculated for each infant. Multiple MFNSS were charted during the
first 48 hours of life. Therefore, all charted Finnegan scores within the first 48 hours were
incorporated into the infant’s TiTE score. For each instance of a detailed score in the infant’s
chart within the first 48 hours of life, scores on three individual items from the Finnegan
(increased muscle tone, tremors when disturbed, and excoriation) were summed. For increased
muscle tone infants could receive a score of zero or two. For tremors when disturbed infants
could receive a score of zero, one, or two. For excoriation infants could receive a score of zero or
one. Then, an average TiTE score was calculated for each infant. Each TiTE score was summed
and divided by the total number of observations for that infant. Average TiTE scores ranged
from 0 to 5. Additionally, a treatment variable was created to indicate whether the infant
received pharmacological treatment (1) for their withdrawal or not (0) during their hospital stay.
TiTE² scores were calculated for each infant according to the exposure categories
described in Isemann et al., (2017), which included buprenorphine only, methadone only, opioids
other than buprenorphine or methadone, and polysubstance (i.e., buprenorphine or methadone
plus additional opioids or the addition of any amphetamine, barbiturate, benzodiazepine, or
cocaine to any opioid). This experiment was unable to replicate the methadone only category
because only two infant participants were categorized as methadone exposed. Thus, these two
participants were categorized in to the “opioids other than buprenorphine” group. A chi-square
test of independence was performed to compare the proportion of infants who received
pharmacotherapy or not for each category of exposure. Post hoc, a value of 0 (associated with no
treatment), 1 (no statistical difference), or 2 (associated with treatment) was assigned based on
the exposure categories’ association with treatment (see Table 2). The TiTE score plus the
exposure “points” reflect the TiTE² score. For example, using the values provided in Table 2, if
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an infant had a TiTE score of 3 and was exposed to an opioid other than buprenorphine they
would receive one additional TiTE2 point and a resultant TiTE2 score of 4.
Table 2.
Category of In Utero Opioid Exposure and Association with Pharmacological Treatment
Experiment 1A.

Experiment 1a
Buprenorphine only
Opioids other than buprenorphine
Polysubstance
Experiment 1b
Buprenorphine only
Opioids other than buprenorphine
Poly-opioid and/or the addition of any
amphetamine, barbiturate, or cocaine
Any opioid plus benzodiazepine and/or
marijuana

Treated

Not
Treated

p-value from Chi
Square

TiTE2
“Points”

32
8
123

115
13
69

p <.001
p =.630
p <.001

0
1
2

32
8
111

115
13
41

p <.001
p =.630
p <.001

0
1
2

17

43

p =.009

0

Note: Methadone only category was not included in Experiment 1a because only two infant
participants were categorized as methadone exposed.
Results and Discussion
Recall that sensitivity and specificity represent accuracy of the diagnostic screening tool.
However, positive and negative predictive values present the probability of correctly identifying
if a patient does or does not have the disease. It is important for a prediction tool to have a
balance between all four metrics. Thus, sensitivity, specificity, positive predictive values, and
negative predictive values were calculated for the TiTE and TiTE² scores using the cross tabs
function in SPSS version 24.0 and are presented in Table 3. Following the structure of the
Isemann and colleagues’ (2017) analysis, two prediction models were examined: one predicting
pharmacotherapy (treatment) and one predicting no pharmacotherapy (no treatment). Within the
predicting treatment model, TiTE scores were dichotomized such that scores greater than or
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equal to 4 and TiTE2 scores greater than or equal to 5, were coded as “1” and scores less than 4/5
were coded as “0”. Within the predicting no treatment model, TiTE and TiTE2 scores were
dichotomized such that scores less than or equal to 1 were coded as “1” and scores greater than 1
were coded as “0”.
Table 3.
Experiment 1A – Pure Replication Tool Validation (Sensitivity and Specificity Analysis).
TiTE Score Predicting No Pharmacotherapy
TiTE Score Predicting Pharmacotherapy
Not Treated Treated
Treated Not Treated
61
18
8
1
Score  1
Score  4
Score > 1
156
150
Score < 4
160
216
Sensitivity
28.1%
Sensitivity
4.8%
Specificity
89.3%
Specificity
99.5%
PPV
77.2%
PPV
88.9%
NPV
49.0%
NPV
57.4%
TiTE2 Score Predicting No Pharmacotherapy
TiTE2 Score Predicting Pharmacotherapy
Not Treated Treated
Treated Not Treated
33
4
54
12
Score  1
Score  5
Score > 1
179
164
Score < 5
114
200
Sensitivity
15.6%
Sensitivity
32.1%
Specificity
97.6%
Specificity
94.3%
PPV
89.2%
PPV
81.8%
NPV
47.8%
NPV
63.7%
PPV = positive predictive value; NPV = negative predictive value

The sensitivity, specificity, positive predictive values, and negative predictive values
indicated that the TiTE² model was the best model when predicting pharmacotherapy. It was
highly specific (94.3%) with a high positive predicative value (81.8%) and the highest sensitivity
value (32.1%) compared to the other models in our replication. Overall, this experiment
successfully replicated the pattern of results from Isemann and colleagues (2017). However, the
prediction tools have poor sensitivity. Experiment 1B explored whether the low sensitivity could
be improved by revising the categories of polysubstance exposure or changing the cut-off values.
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Chapter 3. Experiment 1B
First, Experiment 1B examined the contribution of additional types of polysubstance
exposure to the sensitivity, specificity, positive predictive values, and negative predictive values
of the TiTE² tool. The poor sensitivity reported in Experiment 1A may be due to the
heterogeneity of the polysubstance category. It is well documented that many women do not
consume a single drug during pregnancy (Davie-Gray, Moor, Spencer, & Woodward, 2013;
D’Apolito & Hepworth, 2001; Johnson, Gerada, & Greenough, 2003). A review from
Switzerland found that 62% of drug-using women took various combinations of heroin,
methadone, cocaine, benzodiazepines, alcohol, and marijuana during pregnancy (Arlettaz et al.,
2005). The effect of polydrug use on NOWS remains unclear and most likely depends on the
particular combination and quantities of drugs used by the mother.
Recent research suggests that prenatal exposure to various psychotropic drugs, in
combination with opioids, doubles the likelihood that newborns will be diagnosed with NOWS
(Huybrechts et al., 2017). Benzodiazepines, for example, may distort the presentation of NOWS
because benzodiazepine withdrawal may only start after the first week of life and continue in a
subtle fashion for up to several months (Iqbal, Sobhan, & Ryals, 2002). Benzodiazepines in
combination with opioids also appear to worsen the severity of NOWS (Sanlorenzo et al., 2019;
Wachman et al., 2018). Infants exposed to combinations of benzodiazepines and opioids had the
most rapid onset of withdrawal and the highest withdrawal scores during the first week of life
compared to infants from single drug-using mothers (Abdel-Latif et al., 2006).
Additionally, the prevalence of marijuana use during pregnancy is increasing (Ryan,
Ammerman, & O’Connor, 2018; Young-Wolff et al., 2017). Previous literature indicates that
exposure to marijuana during pregnancy is associated with increased adverse outcomes in the
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neonatal period, such as low birth weight and increased incidence of neonatal intensive care
admission (Conner et al., 2016; Gunn et al., 2016). However, few studies have examined
concurrent opioid and marijuana use. One recent study reported that newborns with prenatal
marijuana and opioid exposure had decreased odds of NOWS and prolonged hospital stay (Stein,
Hwang, Liu, Diop, & Wymore, 2019). In contrast, O’Connor and colleagues found that prenatal
marijuana use during the third trimester, in addition to buprenorphine use, may increase
likelihood of treatment for NOWS (O'Connor, Kelly, & O’Brein, 2017).
Given the increased concurrent use of marijuana and opioids during pregnancy and the
recent research indicating more severe withdrawal symptoms in benzodiazepine and opioid
exposed newborns, the current experiment examined the impact of additional categories of
polysubstance exposure on pharmacological treatment. If the incorporation of additional
polysubstance exposure categories increases the sensitivity of the TiTE2 without sacrificing the
high positive predicative value, then the TiTE2 1B with additional consideration of
benzodiazepine and marijuana exposure would be a better predictor of which infants require
treatment for NOWS within 48 hours of life than the TiTE2 1A model that broadly defined
polysubstance exposure.
A second explanation for the low sensitivity values obtained in Experiment 1A is that the
cut-off values from Isemann et al. (2017) may not be the optimal cut-off values. Isemann and
colleagues’ (2017) cutoff values were selected with the goal of maximizing positive predictive
values while maintaining at least 25% sensitivity.
Traditionally, the accuracy of a diagnostic test is described by examining sensitivity,
specificity, positive predictive values, and negative predictive values. To describe tests in this
manner requires the test results to be reported as dichotomous outcomes (positive/negative). A
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related way to illustrate the accuracy of a diagnostic test is to conduct a Receiver operating
characteristic curve analysis (ROC). A ROC curve analysis has several advantages. First, in
contrast to single measures of sensitivity and specificity, the diagnostic accuracy, such as area
under the curve (AUC), is not affected by decision criterion. Second, a ROC curve analysis
allows researchers to simultaneously compare several diagnostic tasks on the same subjects
(Hanley & McNeil, 1983). Third, the optimal cut- off value can be determined (Greiner, Pfeiffer,
& Smith, 2000). Previous research has used Youden’s index to determine optimal cutoff values
(Fluss, Faraggi, & Reiser, 2005; Roupp, Perkins, Whitcomb, & Schisterman, 2008). The
selection of one cut-off value for predicting treatment may be more appropriate for an early
screening test.
If the goal of the prediction model is to identify patients requiring treatment before the
typical 5-7-day observation period, the proposed prediction tool is likely one of the first tests
conducted on the patients. Thus, it is essential for the prediction tool to have higher sensitivity
rates. The current experiment explored the three aforementioned potential modifications that
could maximize sensitivity, specificity, positive predictive values, and negative predictive values
for predicting treatment.
Methods
The methods for Experiment 1B were identical to those used in Experiment 1A with the
exception of the calculation of the TiTE² score. Recall that Isemann and colleagues (2017) used
only four exposure categories: buprenorphine only, methadone only, opioids other than
buprenorphine or methadone, and polysubstance. An extra category was added to included
marijuana and benzodiazepine exposure (see Table 4). A chi-square test of independence was
performed to compare the proportion of infants who received pharmacotherapy or not for each
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category of exposure. A value of 0 (associated with no treatment), 1 (no statistical difference) or
2 (associated with treatment) are assigned based on the exposure categories association with
treatment. The TiTE score plus the exposure “points” reflect the TiTE ² score. For example,
using the values in Table 2, if an infant had a TiTE score of 4 and was exposed to buprenorphine
they would receive zero TiTE2 points and a resultant TiTE2 score of 4. Sensitivity specificity,
positive predictive value and negative predictive values were computed along with AUC-ROC
curve analysis.
Table 4.
Exposure Categories for Experiments 1A, 1B, and Experiment 2.
Experiments 1A
Buprenorphine only

(i)
(ii)

Opioids other than
buprenorphine

(iii)

Polysubstance:

(iv) the addition of any
amphetamine, barbiturate,
benzodiazepine, or cocaine to any
opioid

Experiments 1B and 2
(i) Buprenorphine only
(ii) Opioids other than
buprenorphine
(iii)

Polysubstance:

(iv) the addition of any
amphetamine, barbiturate, or
cocaine to any opioid
(v) Any opioid plus benzodiazepine
and marijuana

Results and Discussion
Sensitivity, specificity, positive predictive values, and negative predictive values were
calculated for the TiTE² scores using the crosstabs function in SPSS version 24.0 and are
presented in Table 5. Recall that the TiTE2 scores in the current experiment reflect the
consideration of an additional category of polysubstance exposure and thus differ from the TiTE2
scores discussed in Experiment 1A. Frequencies for the predicting treatment and predicting no
treatment models were calculated based on the same cut-off values described in Experiment 1A.
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The results revealed that the TiTE2 1B was highly specific (96.7%), with high positive predictive
values (87.9%) and low sensitivity (30.4%). These frequencies indicate that modifying the
polysubstance category did not improve sensitivity.
Table 5.
Experiment 1B- Expanded Polysubstance Categories: Tool Validation (Sensitivity and
Specificity Analysis).
TiTE2 Score Predicting No Pharmacotherapy
TiTE2 Score Predicting Pharmacotherapy
Not Treated Treated
Treated Not Treated
43
6
51
7
Score  1
Score  5
Score > 1
169
162
Score < 5
117
205
Sensitivity
20.3%
Sensitivity
30.4%
Specificity
96.4%
Specificity
96.7%
PPV
87.8%
PPV
87.9%
NPV
48.9%
NPV
63.4%
PPV = positive predictive value; NPV = negative predictive value
Because the inclusion of an additional category of polysubstance exposure did not
substantially improve sensitivity scores, we explored the impact of alternative cut-off values. The
frequency data for the selection of alternative cut-off values for predicting treatment and
predicting no treatment on sensitivity, specificity, positive predictive values, and negative
prediction values are presented in the Appendices. The exploratory cutoff analyses showed that
the TiTE2 was still highly specific, with high positive predictive values and low sensitivity when
the 25th and 75th percentiles were used as alternate cut off values. However, using the median as
a single cut off value produced a better balance between the sensitivity, specificity, positive
predictive value and negative predictive value. This suggests that having one single cutoff value
for predicting treatment may have led to a more balanced screening approach. While using the
median score to differentiate between patients that require treatment and patients that not require
treatment improved the model, it is possible that other cutoff values would be more meaningful
than the median.
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An AUC-ROC curve analysis was conducted on the continuous TiTE and TiTE2 scores to
compare diagnostic accuracy among tests and determine optimal cutoff values. The AUC-ROC
analysis and Youden’s index are presented in Figure 1. A cutoff score of 3.85 represented the
TiTE’s and 3.96 represented the TiTE2’s optimal ability to differentiate between treatment and
no treatment while maximizing sensitivity and specificity. Sensitivity, specificity, positive
predictive values, and negative predictive values for these cutoff values are listed in the
Appendices.

Figure 1. AUC-ROC Curve Analysis Examining TiTE, TiTE2 (Exp 1A) and TiTE2 (Exp
1B) Scores
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Furthermore, TiTE² scores from Experiment 1A and Experiment 1B were compared
using an AUC-ROC curve to examine whether the inclusion of additional exposure categories
improved the TiTE² prediction tool (see Figure 1). AUC analysis suggests that both TiTE2 1A
(.776) and TiTE2 1B (.794) prediction models were significantly better than the TiTE (.678).
There was not a significant difference between TiTE2 1A and the TiTE2 1B. Thus, the TiTE2
from Experiment 1A was selected as the better model because it is more parsimonious. The
inclusion of additional polysubstance categories did not increase sensitivity of this prediction
model. It is possible that the low sensitivity of the prediction tools in Experiments 1A and 1B is
due to the items included in the TITE. Perhaps the three items (i.e., muscle tone, tremors when
disturbed, excoriation) were not a good fit for the data in the current study. In order to explore
this possibility, a factor analysis was conducted.
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Chapter 4. Experiment 2
Given that the sensitivity values of Experiment 1A and 1B were not significantly
improved by incorporating additional polysubstance categories or by using alternate cutoff
values, Experiment 2 explored the possibility that the items included in the TiTE prediction
model are not suitable for the current dataset. Thus, an exploratory factor analysis was conducted
on the 21 individual items from the modified Finnegan. A factor analysis is a statistical test
applied to the items in an instrument to summarize the patterns of correlations among the items.
The goal of factor analysis is to decrease the number of items in a long instrument (Maguire et
al., 2013).
Methods
An average score was calculated for each individual item on the Finnegan across the
first 48 hours of life. The factor analysis was guided by Maguire and colleagues (2013). A
principal axis factoring extraction with varimax rotation was selected. A scree plot was used to
estimate the number of factors. The principal axis factor extraction confirmed that the data was
appropriate to conduct a factor analysis and four factors were extracted. The 4-factor solution
explained 36.4% of the total variance.
The ten items that loaded on to four factors formed the components of the new prediction
tools, TEN and TEN2. Individual scores on each of the ten items were summed to create the
TEN. Then, an average TEN score was calculated for each infant, by summing each available
TEN score and dividing by the number of observations. TEN scores could range from 0 to 26. A
chi-square test of independence was performed to compare the proportion of infants who
received pharmacotherapy or not for each category of exposure. A value of 0 (associated with no
treatment), 1 (no statistical difference) or 2 (associated with treatment) are assigned based on the
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exposure categories association with treatment. The TEN score plus the exposure points reflect
the TEN² score.
Results and Discussion
There were no observations of generalized convulsions in the sample. The zero variance
on this item prevented the factor analysis from running in SPSS. Therefore, the MFNSS item,
generalized convulsions, was not included in the present factor analysis. Ten items (crying,
sleeping, excessive sucking, stools, poor feeding, projectile vomiting, moro reflex, tremors
disturbed, tremors undisturbed and increased muscle tone) comprised the new prediction tool—
TEN and TEN2 (see Table 6 for factor loadings and communalities). Factor 3 included
myoclonic jerks, but no other items loaded with it and it did not fit our communalities criteria of
greater than .140; therefore, myoclonic jerks was not included in the TEN prediction mode
Table 6.
Factor Loadings, Communalities (h2), and Percentages of Variances for Principle Factors
Extraction with Varimax Rotation on MFNSS Items
Items
Crying
Sleeping
Hyperactive moro reflex
Tremors: disturbed
Tremors: undisturbed
Muscle tone
Excoriation
Myoclonic jerk
Generalized convulsions
Sweating
Fever
Frequent yawning
Mottling
Nasal stuffiness
Sneezing
Nasal flaring
Respiratory rate
Excessive sucking

Factor 1
.133
-.011
.640
.669
.638
.365
.018
.033
.041
.138
.118
.046
-.094
.042
.266
.308
.009

Factor 2
.491
.395
.207
-.056
-.115
.127
.273
.020
.219
.131
-.053
.005
.138
.125
.141
.259
.565
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Factor 3
.214
.261
-.129
.183
.191
-.133
-.129
.356
.088
-.068
.181
-.096
.286
.347
-.220
-.037
.133

Factor 4
.046
.059
1.06
-.122
-.054
.088
.020
-.098
-.152
-.256
-.195
-.097
.091
.102
.035
-.019
.010

h2
.248
.148
.330
.338
.317
.186
.083
.105
.066
.090
.086
.034
.085
.128
.122
.157
.225

Poor feeding
Projectile vomiting
Bowel movement

.103
.214
.073

.111
-.030
.438

-.012
.045
-.021

.537
.434
-.024

Percentage of Variance

12.74%

9.25%

7.38%

7.04%

.150
.150
.167

Note: Factor loadings > 0.35 are in boldface and retained for that factor. h2 = communality
coefficient. MFNSS represents the Modified Finnegan Neonatal Scoring System.

Sensitivity, specificity, positive predictive values, and negative predictive values were
calculated for the TEN and TEN2 scores using the cross tabs function in SPSS version 24.0 (see
Table 7). To examine which prediction model is better at predicating the eventual use of
pharmacological treatment, TiTE² 1A, TEN, and TEN2 scores were compared using an AUCROC curve (see Figure 2). The results indicate that the TEN2 is a better predictor of treatment
compared to the TEN and the TiTE2 1A. A cutoff score of 4.15 represents the TEN2’s optimal
ability to differentiate between treatment and no treatment while maximizing sensitivity and
specificity.
Table 7.
Experiment 2- Prediction Tool Validation based on Factor Analysis (Sensitivity and Specificity
Analysis).
TEN Score Predicting Pharmacotherapy
TEN2 Score Predicting Pharmacotherapy
Treated
Not Treated
Treated Not Treated
120
70
148
93
Score  4.69
Score  4.15
Score < 4.69
48
147
Score < 4.15
20
122
Sensitivity
71.4%
Sensitivity
88.1%
Specificity
67.7%
Specificity
56.7%
PPV
63.2%
PPV
61.4%
NPV
75.4%
NPV
85.9%
PPV = positive predictive value; NPV = negative predictive value
Note: 4.69, 4.15 indicate cut off values based on AUC-ROC curve analysis and Youden’s index.
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Figure 2. AUC-ROC Curve Analysis Examining TiTE2 (Exp 1A), TEN, TEN2 (Exp 2) Scores

The TEN2 reduces the number of items clinicians would score from 21 to 10 and
incorporates exposure type. The TEN2 prediction model produced the highest AUC value (.821)
and best balance between positive predictive value (61.4%) and sensitivity (88.1%).
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Chapter 5. General Discussion
This study replicates the findings of Isemann and colleagues’ (2017) pair of prediction
tools. The TiTE and TiTE² prediction models were applied to a retrospective dataset collected
from the Appalachian Region. It was important to replicate the TiTE and TiTE2 using a sample
from a rural region like Appalachia because this region has been disproportionally impacted by
opioid use and NOWS (Villiapiano, Winkelman, Kozhimannil, Davis, & Patrick, 2017). If the
goal of prediction models like the TiTE and TiTE2 is to reduce the burden of NOWS and
subsequent developmental outcomes on families, hospital systems, and the country, then the
prediction models need to generalize to regions hit especially hard by the opioid epidemic. Data
from Experiments 1A and 1B successfully replicated the pattern of results presented in Isemann
and colleagues’ (2017) publication. The frequency metrics were highly specific and had high
positive predictive values, but very low sensitivity. While the current study replicated the pattern
of results obtained by Isemann and colleagues (2017), the sensitivity of the prediction tools was
very low. While developing a highly specific prediction model is desirable because it minimizes
the chance of over-treating neonates for their withdrawals symptoms. However, the risk of not
treating patients and prematurely sending them home with caregivers that may not know how to
respond to their withdrawals symptoms also needs to be considered. Therefore, it was important
to explore whether a better balance among all four metrics could be obtained. The selection of
alternative cutoff values for predicting treatment and predicting no treatment did not notably
improve the sensitivity of the TiTE and TiTE2 prediction models.
It is important to note there were a few differences between Isemann et al.’s (2017) study
and the current study. First, the original sample is from a more urban region while this study uses
a sample from a rural region. Second, MFNSS scores with details on scores for individual items
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(rather than overall score) were not available for all infants in the dataset and some infants were
did not have detailed scores recorded during the first 48 hours of life. Additionally, the dataset
did not have consistent information on the time each score corresponded to just the day of life.
This is why the current study used first 48 hours of life rather than 36 as in the Isemann
publication. Lastly, the prediction models created in experiment 2 looked at one viewpoint of the
model (predicting treatment), instead of assessing two viewpoints of the model (predicting
treatment and predicting no treatment).
There are a couple of reasons why the TiTE and TiTE2 prediction models presented in the
current study may have low sensitivity. It could be because there were not enough items within
the prediction tool and the specific items (increased muscle tone, tremors when disturbed and
excoriation) are not the same items that are important in this particular dataset. Additionally,
when considering the impact of polysubstance exposure, it is possible patients did not always
report or the toxicology reports did not include all of the substances mothers used during
pregnancy. In addition, the polysubstance exposure categories were condensed because of the
limited number of participants in certain categories. Also, this study was conducted with a
retrospective dataset, therefore, it may be difficult to draw conclusions because retrospective data
are prone to unintended consequences such as errors in medical chart reporting, missing data,
conflicting information in different chart locations and changes in power and structure
throughout the hospital (Campbell, Sittig, Ash, Guappone, & Dykstra, 2006). Finally, despite the
widespread use of the modified-Finnegan as the “gold standard”, it is assessed in a subjective
manner and does not have established reliability and validity when it comes to making
pharmacological treatment decisions. Zimmerman-Baer and colleagues (2010) empirically
examined modified-Finnegan scores in a non-opioid exposed sample and concluded that a score
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of “8” can be used to differentiate those with narcotic exposure from those without narcotic
exposure. Based on this study, the cutoff score of 8 was not examined as a cutoff score to
differentiate among opioid-exposed neonates who may require treatment although it is often
incorrectly cited as support for treatment decisions. Prediction models such as the TiTE and
TITE2 could help to quantify the severity of withdrawal in drug exposed infants, but future
treatment prediction models need to be developed with observations and data that is not
dependent on modified Finnegan scores. For example, the current study uses information from
the electronic medical records on whether the infant received pharmacological treatment for their
opioid-withdrawal. Pharmacological treatment decisions are made based on the infants’ modified
Finnegan scores. Our prediction model is also built based on pieces of the modified-Finnegan.
Until researchers and clinicians tease apart the dependency of pharmacological treatment
decisions and modified Finnegan scores, the weaknesses of the modified Finnegan scoring
system will also be weaknesses of prediction models constructed from modified Finnegan scores.
In Experiment 2 an exploratory factor analysis examined the possibility that the items
included in the TiTE prediction model were not well-matched for the current dataset. Experiment
2 used Youden’s index cutoff scores in an attempt to maximize the prediction tools’ ability to
differentiate between treatment and no treatment. The TEN and the TEN2 displayed high
sensitivity without sacrificing the positive predictive value. After looking at the AUC-ROC
curves across all experiments, the TEN2 was the best predictor of treatment because it had the
highest AUC and maintained the best balance between all four metrics (i.e., sensitivity,
specificity, positive prediction value and negative predictive value).
If hospitals administered neonatal withdrawal scoring based on the 10 items in the TEN
and TEN2, instead of the full 21 items in the Finnegan, then there might be an increase of
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accuracy and consistency with scoring among nurses/clinicians that assess infants’ severity of
NOWS, because they would only have to focus on assessing the infants withdrawal on 10 items.
Additionally, the ten items that constitute the TEN converged on three main factors. The
organization of items within factors appears to align with previous research efforts. For instance,
one factor contained mostly items related to central nervous system functioning. It is logical for
these items to significantly contribute withdrawal because the central nervous system is heavily
concentrated with opioid receptors. Additionally, the other two factors contain items that relate
to the ESC approach. Recall that ESC is a function-based assessment tool that places focus on
infant’s overall progress and ability to eat, sleep, and be consoled to guide treatment decisions.
One factor that emerged in the current study included items such as crying, sleeping, excessive
sucking, and bowel movements. Future research should examine how the TEN prediction models
align with the ESC literature. The ESC approach is the one of the first alternatives to the
modified Finnegan that has been integrated into hospitals and data from the first empirical
studies should be considered when developing or replicating pharmacological prediction models.
Moreover, future research should replicate the current factor analysis of the TEN
prediction model to examine the generalizability of the prediction models. Critically, replication
studies can increase generalizability, propose meaningful modifications, and improve effect size
estimates (Bonett, 2012).The ultimate goal is to develop a prediction tool that clinicians can
administer to differentiate between infants that require pharmacotherapy and those who do not
within the first 48 hours. Making treatment decisions before the typical 5-7-day window could
potentially reduce length of hospital stay, reduce hospital cost, enhance the mother-infant bond,
and target specific interventions or referrals based on the particular withdrawal symptoms
observed during the first two days of life. In order to maximize the potential of the prediction
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tools clinicians can use an objective scoring tool to differentiate withdrawal symptoms from
typical newborn behaviors (Lucas & Knobel, 2012; Timpson, Killoran, Maranda, Picarillo, &
Bloch-Salisbury, 2019). For instance, Timpson and colleagues (2019) created a reference guide
that provides education about conditions that could interfere with withdrawal symptoms (e.g. wet
diaper). This guide gives nurses instructions on how to score infants with the modified Finnegan,
to ensure that environmental influences are not confounding withdrawal symptoms. This and
other aids could reduce the inconsistencies in the scoring of the modified Finnegan. Until a
measure with better psychometric properties is implemented to measure or quantify withdrawal
in neonates, it will be hard to create a more effective prediction model than the one presented in
the current study (Zimmerman-Baer et al., 2010).
In conclusion, the current study successfully replicated the pattern of results from
Isemann and colleagues (2017). More importantly, the current study extended the original
findings from an urban region to a unique sample from a rural region of Appalachia.
Additionally, the type of prenatal drug exposure is important. All of the current prediction
models were improved when type of drug exposure was included. Finally, the TEN2 prediction
model is the best predictor of pharmacological treatment across all of the models considered in
the current study. The TEN2 created the best balance between sensitivity and positive predictive
value and had the highest AUC value indicating it was better at distinguishing between patients
requiring treatment and patients not requiring treatment.
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APPENDICES
Appendix A: TiTE and TiTE2 Experiment 1A with 25th and 75th Percentile Cutoff Values

TiTE Score Predicting No Pharmacotherapy
TiTE Score Predicting Pharmacotherapy
Not Treated Treated
Treated Not Treated
78
28
65
32
Score  1.33
Score  3
Score > 1.33
139
140
Score < 3
103
185
Sensitivity
35.9%
Sensitivity
38.7%
Specificity
83.3%
Specificity
85.3%
PPV
73.6%
PPV
67.0%
NPV
50.2%
NPV
64.2%
TiTE2 Score Predicting No Pharmacotherapy
TiTE2 Score Predicting Pharmacotherapy
Not Treated Treated
Treated Not Treated
80
16
72
24
Score  2
Score  4.5
Score > 2
132
152
Score < 4.5
96
188
Sensitivity
37.7%
Sensitivity
42.9%
Specificity
90.5%
Specificity
88.7%
PPV
83.3%
PPV
75.0%
NPV
53.5%
NPV
66.2%
PPV = positive predictive value; NPV = negative predictive value
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Appendix B: TiTE and TiTE2 Experiment 1A with Median Cutoff Values
TiTE Score Predicting Pharmacotherapy
Treated
Not Treated
119
108
Score  2
Score < 2
49
109
Sensitivity
70.8%
Specificity
50.2%
PPV
52.4%
NPV
68.9%
TiTE2 Score Predicting Pharmacotherapy
Treated
Not Treated
137
83
Score  3
Score < 3
31
129
Sensitivity
81.5%
Specificity
60.8%
PPV
62.3%
NPV
80.6%
PPV = positive predictive value; NPV = negative predictive value
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Appendix C: TiTE and TiTE2 Experiment 1B with 25th Percentile and 75th Percentile
Cutoff Values

TiTE2 Score Predicting No Pharmacotherapy
Not Treated Treated
83
17
Score  1.75
Score > 1.75
129
151
Sensitivity
39.2%
Specificity
89.9%
PPV
83%
NPV
53.9%
TiTE2 Score Predicting Pharmacotherapy
Treated
Not Treated
86
27
Score  4
Score < 4
82
185
Sensitivity
51.2%
Specificity
87.3%
PPV
76.1%
NPV
69.3%
PPV = positive predictive value; NPV = negative predictive value
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Appendix D: TiTE and TiTE2 Prediction Models Experiment 1B with Median Cutoff
Values
TiTE2 Score Predicting Pharmacotherapy
Treated
Not Treated
129
64
Score  2.88
Score < 2.88
39
148
Sensitivity
76.8%
Specificity
69.8%
PPV
66.8%
NPV
79.1%
PPV = positive predictive value; NPV = negative predictive value

52

Appendix E: TiTE and TiTE2 Experiment 1B with Youden’s Index Cutoff Values
TiTE Score Predicting Pharmacotherapy
Treated
Not Treated
9
159
Score  3.85
Score < 3.85
1
216
Sensitivity
90.0%
Specificity
57.6%
PPV
5.36%
NPV
99.5%
TiTE2 Score Predicting Pharmacotherapy
Treated
Not Treated
86
82
Score  3.96
Score < 3.96
27
185
Sensitivity
76.1%
Specificity
69.3%
PPV
51.2%
NPV
87.3%
PPV = positive predictive value; NPV = negative predictive value
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